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Abstract Rheumatic and musculoskeletal diseases (RMDs)
represent a multitude of degenerative, inflammatory and auto-
immune conditions affecting millions of people worldwide.
Persons with these diseases may potentially experience severe
chronic pain, joint damage, increasing disability and even
death. With an increasingly ageing population, the prevalence
and burden of RMDs are predicted to increase, placing greater
demands on the global practice of rheumatology and related
healthcare budgets. Effective treatment of RMDs currently
faces a number of challenges in both the developed and
developing world, and individual countries may face more
specific local challenges. However, limited understanding of
the burden of RMDs amongst public health professionals and
policy-makers means that these diseases are often not consid-
ered a public health priority. The objective of this review is to
increase awareness of the RMDs and to identify opportunities
to address RMD challenges on both a local and global scale.
On 26 September 2014, rheumatology experts from five dif-
ferent continents met at the World Forum on Rheumatic and
Musculoskeletal Diseases (WFRMD) to discuss and identify
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some key challenges for the RMDs community today. The
outcomes are presented in this review, focusing on access to
rheumatology services, diagnostics and therapies, rheumatol-
ogy education and training and on clinical trials, as well as
investigator-initiated and epidemiological research. The long-
term vision of the WFRMD is to increase perception of the
RMDs as a major burden to society and to explore potential
opportunities to improve global and local RMD care.
Keywords Clinical trials . Diagnostic tests . Epidemiology .
Medical education . Public health . Rheumatic diseases
Introduction
The term rheumatic and musculoskeletal diseases (RMDs)
largely encompasses over one hundred degenerative, inflam-
matory and auto-immune conditions which in their most ad-
vanced form are associated with severe pain, joint damage,
disability and even death. In the 2010 World Health Organi-
zation (WHO) Global Burden of Disease Study, RMDs were
reported to be the second leading cause of disability world-
wide, as measured by years lived with disability [1]. Estimates
suggest that almost 2 billion people are affected worldwide [1]
imposing huge financial costs; in Europe alone, RMDs are
associated with an economic burden of over €200bn per year.
The global burden of individual RMDs has recently been
addressed in a series of individual articles (Fig. 1) [2–7].
Nevertheless, awareness of the burden of RMDs amongst
policy-makers remains limited for both paediatric and adult
manifestations of diseases. With an ageing global population,
the prevalence and burden of RMDs in developing and devel-
oped countries1 is predicted to increase, resulting in reduced
quality of life and loss of work productivity, while placing a
major burden on national healthcare systems [8, 7].
Worldwide inequalities exist in access to clinical care,
rheumatology training and research opportunities. However,
the burden of disease is often higher in developing countries,
due to limited access to clinical services and treatments [9,
10]. Increasing awareness amongst policy-makers of the
health problems and economic burdens associated with
RMDs, in order to prioritise the RMDs in healthcare planning,
will help ensure the best possible patient outcomes. Over the
past decade, the WHO has developed a global strategy for the
treatment of many non-communicable diseases; however,
RMDs are not mentioned [11] and are not indexed as a topic
on the WHO website. Other initiatives such as the Bone and
Joint Decade (BJD) [11] and the European League Against
Rheumatism (EULAR) have advocated for priority to be
given to RMDs at the policy level, to reflect the significant
challenges these conditions pose to public health. This review
identifies some of the main challenges and opportunities for
the RMDs community today (Fig. 2).
Methodology
A preliminary PubMed literature search focusing on chal-
lenges in the areas of RMDs clinical care, education and
research was conducted to identify key questions for the
authors to address. Subsequently, a pre-agreed agenda was
discussed at the inaugural meeting of the World Forum on
Rheumatic and Musculoskeletal Diseases (WFRMD), held in
Abu Dhabi on 26 September 2014. A more focused literature
search was then conducted on the key topics identified, with
further discussions between authors during development of
the final manuscript.
Challenges within the clinical care services
According to the WHO, a key component of a well-
functioning health system is to provide equitable access to
people-centred care [12]. Availability of healthcare workers,
clinical services, affordability of care and cultural acceptabil-
ity of treatment are all important factors [13]. Any disparity
and inadequacy in patient access to healthcare professionals,
including primary care providers (PCPs2) rheumatologists,
orthopaedic surgeons, physical medicine and rehabilitation
specialists, nurses, occupational therapists and physiothera-
pists can significantly delay diagnosis of RMDs and treatment
initiation, both of which are key to minimising disease pro-
gression and improving patient outcomes [14, 15].
Access to rheumatology services
Although the number of rheumatologists in developed coun-
tries far exceeds that in developing countries, there are world-
wide (Table 1) and regional shortfalls in the provision of
rheumatologists. A Markov prediction model examining sup-
ply and demand for rheumatologists in the United States (US)
found that the situation is likely to worsen over the coming
decades [16], largely due to an ageing population. Increasing
rates of non-communicable diseases, on top of existing en-
demic and emerging diseases, are also likely to compete for
limited resources [17].
1 For the purpose of this manuscript, developing countries are defined by
World Bank criteria as low- and middle-income economies, i.e. those
with gross national income per capita calculated using the World Bank
Atlas method, of $1045–12,746 in 2013.
2 PCPs are healthcare practitioners who provide primary care for patients,
defined by the WHO as first-contact, accessible, continued, comprehen-
sive care, which coordinates with other specialists to provide any other
care the patient may need.
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Analysis of the distribution of rheumatology practices
across the US using the 2010 American College of Rheuma-
tology (ACR) membership database found that of 3920
practising rheumatologists, 90 % worked in metropolitan re-
gions, with only 3 % practising in micropolitan areas (popu-
lations <50,000) and 7 % practising in rural areas [18].
Fig. 2 Summary of the global challenges and opportunities facing rheumatology today
Fig. 1 Rheumatic and
musculoskeletal diseases (RMDs)
and their estimated prevalence
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Similarly, in Canada and the Latin American and Caribbean
region, rheumatologists are distributed mainly in large cities,
leaving micropolitan and rural areas underserved. Findings
from two studies in Ontario reported fewer rheumatologist
visits for arthritis and inflammatory arthritis patients who
lived in less populated areas with lower socioeconomic status
[19, 20]. As a consequence of the worldwide shortage of
rheumatologists, RMD patients are more likely to receive
attention from a PCP, who may have no formal training in
rheumatology [21, 22].
While shortages are documented in rheumatology care in
general, paediatric rheumatology care is severely restricted. In
Africa, there are only two paediatric rheumatologists [23],
with an estimated 159–180 practising paediatric rheumatolo-
gists across the Latin American and Caribbean regions, 325 in
the US and around 60 paediatric rheumatologists in the UK. In
India, reports suggest that <50 % of the 1.3 million children
with juvenile idiopathic arthritis (JIA) are diagnosed during
the first year of their illness due to limited paediatric rheuma-
tology care [24].
Pan American League Against Rheumatism (PANLAR)
and National Rheumatology Societies in the Latin American
and Caribbean Region recognise that the number of rheuma-
tologists is insufficient to meet demands [17, 25]. The use of
geospatial analysis could aid understanding of the access to




a Number of full-time equivalent
rheumatology physicians, May
2011
b N um b e r o f p r a c t i s i n g
rheumatology physicians per
100,000, May 2011
c N um b e r o f p r a c t i s i n g
rheumatology specialists, 2010
d Number of rheumatology
physicians (with specialist
certificate), May 2011
eData on file, Italian Society for
Rheumatology
f Data from PANLAR National
Workforce Survey, 2012
g Number of rheumatologists
estimated based on personal
c o m m u n i c a t i o n w i t h
rheumatologists. Population data
were obtained from World Bank
mid-year estimates [70] based on
year for which the number of
rheumatologists were available;
2013 population data was used
for 2014 data as 2014 population
estimates were not yet available.
Ratios were calculated based on
number of rheumatologists divid-
ed by population estimates for
that year





UK [64] 2011 63,258,918 531a 0.84
Ireland [65] 2011 4,576,794 ∼23 0.5b
France [66] 2010 65,023,142 2,470c 3.80
Germany [67] 2011 81,797,673 757d 0.93
Italye 2011 60,782,668 800 1.3
North America
USAf 2012 313,873,685 5602 1.78
Canada [68] 2013 35,158,304 342 0.97
Middle East
Omang 2014 3,632,444 20 0.55
UAEg 2014 9,346,129 40 0.43
Kuwaitg 2014 3,368,572 30 0.89
Qatarg 2014 2,168,673 12 0.55
Saudi Arabiag 2014 28,828,870 120 0.42
Bahraing 2014 1,332,171 4 0.30
Latin America
Uruguayf 2012 3,395,253 105 3.09
Brazilf 2012 198,656,019 1543 0.78
Colombiaf 2012 47,704,427 136 0.29
Nicaraguaf 2012 5,991,733 4 0.07
Mexicof 2012 120,847,477 568 0.47
Asia
China [69] 2007 1,317,885,000 2216 0.17
Indiag 2014 1,252,139,596 ∼200 0.02
Pakistan [22] 2014 182,142,594 20 0.01
Thailand [42] 2014 67,010,502 150 0.22
Africa
Comorosg 2014 734,917 0 0
Nigeriag 2014 173,615,345 22 0.01
Djiboutig 2014 872,932 0 0
Australia
Australiag 2014 23,130,900 307 1.33
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geographic area [26]. A study of US Medicare patients found
that increased driving distance to rheumatologists was associ-
ated with decreased odds of diagnosis with rheumatoid arthri-
tis (RA) [27]. Providing up-to-date information about the local
supply of rheumatologists, and additional funds for training
programmes, could attract new rheumatologists to under-
served regions through migration and expansion [18]. Never-
theless, in some countries, it may never be possible to train a
sufficient number of rheumatologists. As such, PCPs may
need to play a greater role in early rheumatological care and
provide a more effective triage system. The early arthritis
clinic model is gaining popularity, in which PCPs are trained
to screen patients with RMDs and triage the most severe and
urgent cases, such as primary inflammatory arthropathies [28].
The use of telephone and videoconference consultations may
provide an effective means to improve access to rheumatology
care in rural areas. This would allow for both direct patient
care by rheumatologists and support of PCPs who can be
educated, mentored and given diagnostic and management
advice [9, 29–32].
Access to diagnostics
Early diagnosis and treatment of RMDs in the ‘window of
opportunity’ following the onset of symptoms are crucial to
avoid long-term complications but requires specialist knowl-
edge [33]. When appropriate treatment is started early, medi-
cal costs, disability and work limitations can be reduced [33].
Currently, there is no single preferred method of diagnos-
ing RMDs, and tools used are dependent on the PCPs’ own
knowledge [34]. Clinical diagnoses are typically supported by
blood tests (e.g. erythrocyte sedimentation rate, C-reactive
protein, anti-nuclear antibodies, rheumatoid factor) and imag-
ing modalities. However, lack of expertise or funding and
limited imaging facilities can create barriers to more system-
atic use of magnetic resonance imaging (MRI) and ultrasound
in some regions, including Latin America [35]. Use of dual-
energy X-ray absorptiometry (DXA) to measure bone mineral
density is the standard diagnostic technique for osteoporosis
but costs are relatively high, with limited access to equipment
in many developing countries [36]. Absolute fracture risk
calculators such as the FRAX model (a validated web-based
algorithm) may provide a suitable alternative [37]. Common
serological tests such as rheumatoid factor and anti-nuclear
antibodies are available in all African countries, but rural areas
invariably do not have such facilities. In resource-poor set-
tings, with limited access to diagnostics, the assessment of
disease activity using clinical rather than laboratory measures
could be advantageous (e.g. the modified systemic lupus
erythematosus [SLE] Disease Activity Index [SLEDAI]) [38].
Further development of rapid blood or serum-based diag-
nostic tests to screen for auto-immune RMDs should be
encouraged. Point-of-care tests for early detection of RA using
auto-antibodies or rheumatoid factor require only a single
drop of blood and can be performed within minutes [39].
These advanced and non-invasive diagnostic tools represent
an expanding area of interest for rheumatologists. Use of
capillaroscopy to examine microcirculatory impairment is
also gaining popularity amongst Western and Eastern coun-
tries, with dedicated study groups at ACR and EULAR
congresses.
Musculoskeletal ultrasound (MSUS) is playing an increas-
ingly important role in optimising clinical assessment of pa-
tients with RMDs and substantially improves therapeutic and
diagnostic capabilities [40]. However, training is expensive,
labour intensive and the learning curve is very steep [41], with
huge variation between countries signifying the need for an
international consensus on MSUS training [41]. ACR,
EULAR and PANLAR have all developed guidelines and
international training programmes for MSUS.
Access to therapies
Access to suitable therapies is largely dependent on the na-
tion’s health system, drug availability and the economic status
of the country. In wealthy countries, there may be easy access
to therapies through government-supported funding or insur-
ance, whereas in poorer countries, patients are offered treat-
ment solely based on their ability to pay for it. In Thailand,
patients in the Universal Coverage Scheme can only access
medicine on the National List of Essential Medicines, which
does not include biologics, and treatment regimens are mod-
ified according to the level of patient health insurance cover
[42]. Even in the US, patients with insurance coverage may be
forced by the insurer to pay high co-payments or “co-insur-
ance”. These additional payments may place vital treatment
out of the patient’s grasp. The ACR spends great time and
resources to combat these onerous practices in cooperation
with its advocacy partner, the Arthritis Foundation. In Africa,
immunosuppressants for the treatment of SLE are unafford-
able for the majority of patients, or even state healthcare
budgets [38]. Such variable access to therapies can deny
implementation of established RMD treatment guidelines in
developing countries, such as EULAR recommendations on
the use of biologics in RA [43].
In 2011, a cross-sectional study across 46 European coun-
tries found that patients with RA in lower income countries
had reduced access to both biologic and synthetic disease-
modifying anti-rheumatic drugs (bDMARDs and sDMARDs)
[13]. PANLAR has proposed that biosimilars could improve
therapy access for patients with RA in the Latin American
countries, as could decreasing custom fees and taxes for drugs
and joint prostheses [25]. Informal discussions with manufac-
turers in the US indicates that the cost of biosimilars may not
be significantly reduced compared to biologics, with ≤20 %
price reduction anticipated. However, in the Norwegian tender
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system, the biosimilar Remsima was offered for a price 39 %
lower than that for Remicade [44].
Inequities exist in the availability and consistency of supply
of established cost-effective medications for RMDs, including
non-steroidal anti-inflammatory drugs (NSAIDs; such as ibu-
profen, naproxen and diclofenac) and sDMARDs, such as
hydroxychloroquine, sulfasalazine, methotrexate (MTX) and
leflunomide. In some African countries, disease-modifying
anti-rheumatic drugs (DMARDs) are usually stocked by only
a few pharmacies. The time taken for patients to receive
sDMARDs may also vary depending on the healthcare sys-
tem; in Brazil, it can take 1–4 years before a patient in the
public healthcare system receives a sDMARD, compared with
<2 years in private healthcare [35]. In South Sudan, DMARDs
are not generally available and in other African countries,
similar issues exist with SLE medications, alongside the fear
of buying counterfeit medications locally [38]. Consequently,
patients and their doctors need to obtain medicines from other
countries, often at great expense [45, 38].
The concept of selling essential medicines in low- and
middle-income countries at lower prices than in industrialised
countries has received widespread support from industry,
policy-makers and academics [46]. However, tiered pricing
does not necessarily result in the lowest sustainable prices or
lead to price reductions over time [46]. Further research is
needed to determine whether a tiered pricing model could
successfully increase access to RMD treatments in developing
countries.
Education of rheumatologists and other experts in RMD
care
Successful education in the RMDs requires a collaborative,
constructive, and contextual approach, aimed at providing
education across professions. To address the current chal-
lenges in education across the medical education continuum,
leadership of RMD experts specialising in medical education,
research and service leadership will be mandatory.
Medical school
Early exposure of medical students, residents and students of
other relevant health professions to rheumatology ‘culture’ is
vital to improve awareness of the RMDs and increase the
number of students and residents considering this field of
study. Inmany countries, PCPs lack knowledge of the nuances
of RMDs, leading to misconceptions about the most appro-
priate treatment options, delayed diagnoses and a limited
awareness of conditions such as the spondylarthropathies.
To date, rheumatology education has not been a high
priority in many medical school curricula and consequently
does not allow sufficient exposure of students to the RMDs
[47]. A 2008 survey of Canadian medical schools found that
the total average time spent in musculoskeletal physical ex-
amination teaching was just 4–7 h over 4 years of study, and
58 % of teaching was performed by non-RMD experts [48,
49]. In part, this may be due to the limited number of rheu-
matologists and other health professionals trained as educators
and educational leaders, who can combine their expertise in
both RMDs and education to increase focus on RMDs across
the education continuum.
Generalist training
A US survey of PCPs evaluated their experience with the use
of DMARDs in RA and found that only a minority initiated
this therapy option and PCPs generally had a high level of
discomfort prescribing DMARDs [50]. A similar US survey
to assess the use of European and American gout treatment
recommendations found that of 838 PCP respondents, only
half reported optimal treatment practices for the management
of acute gout, and <20 % for intercritical or tophaceous gout,
indicating care deficiencies [51]. Typically, PCPs are over-
extended taking care of other chronic diseases, such as obesi-
ty, hypertension and diabetes, which may explain their re-
stricted time devoted to increased understanding of RMDs.
In a survey of undergraduate nursing, occupational therapy
and physiotherapy courses in the UK, educationalists reported
only limited coverage of rheumatology [52, 53]. However, the
ACR’s Association of Rheumatology Health Professionals
(ARHP) offers a successful programme called Advanced
Practice Rheumatology, with a modular online course and
hands-on training for advanced practice nurses and physi-
cian’s assistants. Other societies have similar programmes
such as the Rheumatology Nurses Society (RNS), committed
to the education of nurses working in rheumatology. In the
Latin American countries, a PANLAR-endorsed multinational
rheumatology e-learning and presence training diploma pro-
gramme for nurses and health professionals has been
established and includes a hands-on and theoretical MSUS
course. Greater provision of online training courses in devel-
oping countries, at reduced costs, could further enhance train-
ing opportunities.
Paediatric rheumatology is a particular area in which PCPs
require further education. A review of the barriers
constraining access to appropriate paediatric rheumatology
care found that, in general, US paediatricians had little or no
training in RMD health and had relatively poor physical
examination and diagnosis skills [54]. Introduction of a man-
datory RMDs rotation for paediatric residencies could help to
improve awareness and understanding of these cases [54]. The
ACR currently funds visiting paediatric rheumatology profes-
sorships, to bring in-depth training to paediatric programmes
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and provide much needed support for paediatric care in de-
veloping countries.
Specialist training
Collaborations between rheumatology associations and uni-
versities could help strengthen existing teaching, provide core
knowledge of the RMDs to all practitioners and encourage
rheumatology as a specialty within that region. The ACR
provides training and research grants for medical students,
residents, fellows and clinicians in rheumatology, and has
convened an international task force to assess the need for,
and distribution of, educational tools. Similarly, the EULAR
Committee for Education and Training (ESCET) offers bur-
saries for students and rheumatologists worldwide to attend
online and postgraduate courses on RMDs. The Emerging
EULAR Network (EMEUNET) is a working group of young
rheumatology clinicians across 77 countries that facilitates
education in RMDs. EULAR also offers a subsidised online
rheumatology course.
Nevertheless, there is a general lack of training opportuni-
ties for those considering specialisation as rheumatologists.
For example, in Nigeria, there is only one rheumatology
training centre in the country. In Thailand, there are only 15
rheumatology training positions available each year, but this
could be improved by increasing the number of grants avail-
able from the Thai Ministry of Public Health [42]. Of the
current rheumatologists practising in India and Pakistan, 20
and 50 %, respectively, received their training elsewhere [22].
In the United Arab Emirates, Bahrain and Oman, all rheuma-
tology training takes place overseas, while in Kuwait, Qatar
and Saudi Arabia residents have hybrid programmes of local
and international training. Although overseas accreditation
can be beneficial, the majority who train in the West do not
return to their native countries to practice rheumatology [22].
Continuing education
Regional and national rheumatology leagues should help to
deliver courses with clear curricular goals. The Chinese Rheu-
matology Association is working with medical schools to
provide intensive training sessions, lectures and comprehen-
sive curricula for the purpose of continuing medical education
(CME) [55]. The ACR Rheumatology Research Foundation
also has programmes for this, plus nascent programmes to
attract college students to rheumatology and other rheumatol-
ogy health professions.
Reduced registration fees or sponsorship to attend interna-
tional congresses presents an ideal opportunity to promote
‘rheumatology without borders’ so that physicians worldwide
can learn about the latest advances in the treatment of RMDs
[56]. The impact of educational forums could be broadened
via free post-congress web links that disseminate talks and
workshops (using podcasts, videos, slide sets, handouts and
translated materials) to target audiences that are unable to
attend the congress due to lack of time or funding, travel
requirements and language barriers. In addition, world rheu-
matology leaders could travel to developing regions to share
their knowledge and expertise, e.g. the International Ad-
vanced Abu Dhabi Rheumatology Review Course (and nu-
merous other meetings around the world).
CME programmes are currently offered by ACR, EULAR,
American Board of Medical Specialties (ABMS), Royal Col-
lege of Physicians (RCP), Asia Pacific League of Associations
for Rheumatology (APLAR), PANLAR and African League
against Rheumatism (AFLAR). However, there is a general
lack of programmes in Africa, Asia and the Middle East. The
International League of Associations for Rheumatology
(ILAR) Grants Program also provides opportunities to ad-
vance the education and clinical practice of rheumatology in
developing countries but has limited resources, with grants
totalling $150,000 in 2014. A successful ILAR-supported
project running from 2012 to 2013 addressed a particular need
in Zambia to enhance paediatric and adult rheumatology
education and practice [57]. Similarly, the ILAR-funded
UWEZO Musculoskeletal Health training project aims to
provide medics in Kenya with appropriate training to diagnose
and treat RMDs (UWEZO means ‘capability’ in Swahili).
Trained medics can then go on to train community health
workers in their region.
The Arthritis Alliance of Canada has developed a coordi-
nated national framework for models of care for patients with
inflammatory joint diseases. Similarly, the Canadian Rheuma-
tology Association (CRA) is a strong and committed organi-
sation for RMDs, forming alliances with the Canadian Med-
ical Association and the Royal College of Physicians and
Surgeons, and increasing relationships with other organisa-
tions including ACR and PANLAR.
Patient awareness of RMDs
In some areas of the world, a lack of basic education and
literacy, poorer socioeconomic status and cultural beliefs can
influence the decision of patients to seek medical attention
from a PCP, or they may only seek help from alternate care
practitioners [9]. Many patients see the aches and pains asso-
ciated with arthritis as a part of life and do not seek medical
opinion.
Prevention strategies with campaigns to educate and raise
awareness about RMDs may increase the likelihood of a
patient approaching their PCP and may also increase a pa-
tient’s understanding of their disease, ultimately improving
their compliance with treatment decisions. The Patient Asso-
ciation inside EULAR (PARE) organises courses and local
training sessions for patients across 37 countries. Existing
campaigns to educate the public about health issues such as
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diabetes, hypertension and obesity could also be expanded to
include RMDs.With the increasing use of smartphones world-
wide, patient self-management or education programmes in-
tegrated into social media technologies or mobile applications
might broaden patient access to information about their dis-
ease [58]. Looking ahead, organisations such as the US Ar-
thritis Foundation or the ACR Simple Tasks campaign, which
has gained the interest of rheumatology associations world-
wide, may play an important role in raising patient and phy-
sician awareness and educating policy-makers about the value
of rheumatology education [33].
Research challenges
The impact of financial, political, social, or environmental
factors on the opportunity to conduct clinical, epidemiologi-
cal, as well as basic and translational research creates major
challenges worldwide. In many countries, including the US
and Canada, government funding for rheumatology research
is diminishing and academics are being forced into the clinic,
reducing their research time. In countries with major shortfalls
in the rheumatology workforce, health systems are likely to
need all rheumatologists for full-time clinical practice, leaving
insufficient time for research activities.
Clinical trials research
Ethnicity may influence the manifestation of various RMDs,
due to underlying genetic differences, environmental factors,
cultures and socioeconomic status [42]. However, pharmaceu-
tical companies running randomised controlled trials (RCTs)
have tended to conduct trials in Western industrialised coun-
tries, limiting the amount of information for the effectiveness
and safety of treatments in non-Western populations (Table 2).
Although more trials are now occurring in Eastern Europe and
India due to a lack of biologic-naïve patients in the West, the
Middle East and North Africa region sponsor less than 1 % of
global clinical trials [59].
Action is needed to encourage pharmaceutical companies
to conduct RCTs which are more generalisable to different
populations. However, a number of challenges must be over-
come including training individuals to successfully manage
the trials, differences in language, culture, social and health
literacy; inaccurate translation and high levels of illiteracy can
be problematic [59]. Establishing local Clinical Research Or-
ganisations could help overcome regulatory bottlenecks, as
they are more likely to understand local regulations and logis-
tic needs [59]. More discussion groups at rheumatology con-
gresses such as ACR, EULAR, AFLAR and PANLAR on
how to conduct RCTs may also help to identify potential
issues for developing countries. In developed countries,
increased dialogue is needed between drug regulatory bodies
such as the US Food and Drug Administration (FDA) and
European Medicines Agency (EMA), pharmaceutical compa-
nies and researchers coordinating RCTs. Recently, collabora-
tion between EULAR and the EMA has been officialised,
with EULAR members making recommendations together
with EMA officers.
Investigator-initiated research
There are many existing programmes to support investigator-
initiated RMDs research including the Canadian Initiative for
Outcomes in Rheumatology Care (CIORA) which offers
awards to new clinicians to carry out independent arthritis
research. Similarly, the ACR Rheumatology Research Foun-
dation funds promising research to help bridge investigators to
sustainable support from the National Institutes of Health
(NIH). In China, government funding for rheumatology re-
search has increased substantially in the past decade, leading
to many high-quality publications and international collabo-
rations [55]. In the recent Arab League Against Rheumatism
(ARLAR) meeting, 100 research scholarships were awarded
to young rheumatologists. The Paediatric Rheumatology In-
ternational Trials Organisation (PRINTO), Paediatric Rheu-
matology European Society (PReS) and Childhood Arthritis
and Rheumatology Research Alliance (CARRA) also aim to
facilitate and coordinate clinical trials and research in paedi-
atric RMDs.
Table 2 Number of regis tered cl inical t r ia ls l is ted on
ClinicalTrials.Gov for different RMDs by region
Region Number of registered trials
Rheumatoid
arthritis
Osteoarthritis Gout Systemic lupus
erythematosus
Africa 75 24 8 13
East Asia 253 144 13 86
Europe 678 530 31 104
Latin Americaa 243 65 9 59
Middle East 89 53 2 16
North America 693 821 85 238
North Asia 160 12 12 30
Pacifica 102 43 9 16
South Asia 48 16 2 16
Southeast Asia 61 39 8 24
Information based on number of clinical trials registered on
ClinicalTrials.Gov by RMD topic, as of 4 November 2014. Studies with
no locations are not included; studies with multiple locations are included
in each region containing locations
a Latin America values obtained by adding number of trials in Central
America and South America
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Epidemiological research
Real-life efficacy and safety data from registries provide a
valuable source of data for the RMDs. For example, the
British Society for Rheumatology Biologics Register
(BSRBR) has been used to compare the risk of tuberculosis
between different biologics used to treat RA [60]. The nascent
ACR RISE registry will collect point-of-service data on pa-
tients in various settings, with international interest in joining
this registry. Similarly, BIOBADAMERICA is a Latin Amer-
ica and Caribbean registry of 15 nations that collects informa-
tion on all relevant adverse events in patients on biologics
[61].
To date, the most comprehensive effort to collect data for
the RMDs is the Global Burden of Disease (GBD) 2010 study,
which estimated the global burden of RMDs and showed that
the prevalence and burden of RMDs are exceptionally high
throughout the world [2–7, 62]. However, for many regions,
burden estimates had to be derived through predictive model-
ling [8].
Country-based data is very useful for local clinicians to
follow their own patients who may be different in terms of
disease severity, access to care, and comorbidities. Such data
is also beneficial when negotiating with local governments
and payers to provide evidence for the benefit and safety of
more expensive treatments. Despite the obvious advantages of
collating such information, obtaining the funding to set up
new registries can be difficult. Furthermore, academics are not
necessarily engaged in this type of activity. In many develop-
ing countries, health records are still paper-based; the intro-
duction of electronic records is necessary to maximise data
collection and simplify registry management.
The WHO-ILAR Community Oriented Programme in the
Rheumatic Diseases (COPCORD) was created to gather data
on RMDs, with an emphasis on developing rural economies
[63]. The COPCORD Core Questionnaire (CCQ) has provid-
ed a useful way of collecting grass-roots data on the preva-
lence of RMDs in developing countries. However, the meth-
odology is quite labour intensive, and design and methods are
limited by stringent budgets, imposing deviations in the core
protocol [63]. To harmonise epidemiological data for the
RMDs, valid and standardised questions should be developed
for use in population-based health interview and examination
surveys.
Conclusions
The high prevalence and burden of RMDs presents a number
of global challenges for the practice of rheumatology and
more generally for chronic diseases. Issues concerning access
to clinical care services, rheumatology education and research
are particularly problematic in developing countries and rural
areas, yet challenges faced in developed countries hinder the
progress of RMD healthcare worldwide. By increasing aware-
ness of the burden of RMDs at the policy-maker level and
identifying key challenges, it may be possible to identify
realistic opportunities to address the global RMDs problem.
The WFRMD aims to address important challenges for the
RMDs by facilitating discussions with rheumatology experts
and lobbying stakeholders, internal and regional rheumatolo-
gy associations, local governments and the WHO to raise
awareness of these prevalent and burdensome diseases.
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